1. Trial profile The FIELD study investigators, Lancet Published online November 14, 2005

2. Baseline characteristics and medication The FIELD study investigators, Lancet Published online November 14, 2005

3. Plasma concentration of lipids at baseline and study close, with treatment group differences during follow-up The FIELD study investigators, Lancet Published online November 14, 2005

4. Kaplan-Meier curves of compliance with study medication (shown as time to permanent discontinuation) and cumulative risk curves of uptake of other lipid-lowering agents, by treatment group The FIELD study investigators, Lancet Published online November 14, 2005

5. Effect of treatment on primary and secondary outcomes The FIELD study investigators, Lancet Published online November 14, 2005

6. Cumulative risk curves of time to first events CHD=coronary heart disease. MI=myocardial infarction. CVD=cardiovascular disease. The FIELD study investigators, Lancet Published online November 14, 2005

7. Effect of fenofibrate treatment on total cardiovascular disease (CVD)events (CVD death,myocardial infarction,stroke,co ronary,or carotid revascularisation) * 102 cm for men >88 cm for women ‡Low HDL cholesterol plus high triglyceride The FIELD study investigators, Lancet Published online November 14, 2005

8. Patients on concominant medication between baseline and study close The FIELD study investigators, Lancet Published online November 14, 2005

9. Clinical and laboratory evidence of safety of fenofibrate The FIELD study investigators, Lancet Published online November 14, 2005